reMYND

reMYND

Foundation date

07/02/2002

Sector

#Biotechnology - Therapeutics

Subsector

• #Therapeutics - Small molecules
• #R&D Services - CRO (Contract Research Organization)
• #R&D Services - Screening

Therapeutic areas

• #Diseases of the blood and blood-forming organs - immune disorders
• #Diseases of the nervous system
• #Endocrine - nutritional and metabolic diseases

reMYND actively drives the development of disease modifying treatments against Alzheimer’s disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation (CRO) or through its own drug discovery & development (DDD).